Beyond AD, the therapeutic relevance of FASN inhibition extends to various diseases, including cancer, fatty liver disease, obesity, and type 2 diabetes [26–29], underscoring its broad therapeutic potential. Here, FASN is linked to obesity due to melanocortin 4 receptor deficiency.